Epirus and Livzon collaborate on copy biologicals for China

Biosimilars/News | Posted 10/10/2014 post-comment0 Post your comment

US-based Epirus Biopharmaceuticals (Epirus) announced on 25 September 2014 that it had signed a collaboration agreement with Chinese biotechnology company Livzon Mabpharm (Livzon).

Shaking hands V13D29

The agreement will see Epirus and Livzon work together to develop, manufacture and commercialize up to five copy biologicals for the Chinese market. The first product the companies will work together on is BOW015 (infliximab). Epirus received approval for its infliximab similar biologic in India under the brand name Infimab in September 2014 [1].

Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan and will also serve as the preferred supplier of BOW015 in these territories.

Dr Daotian Fu, CEO of Livzon, commenting on the agreement said that ‘Epirus’ robust pipeline, business strategy and experienced management coupled with the market potential of biosimilars, made this an exciting collaboration for Livzon. We look forward to building a substantial biosimilars business for the China market.’

China, one of the largest pharmaceutical markets in the world, has yet to issue biosimilars guidelines, although domestic copy biologicals have been on the market in China for 20 years. Copy biologicals in China therefore have to go through a new drug or generic drug approval process [2].

Editor’s comment
It should be noted that ‘copy biologicals’ approved in China and ‘similar biologics’ approved in India might not have been authorized following as strict a regulatory process as is required for approval of biosimilars in the European Union. European Medicines Agency regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related articles
Strategy for biosimilars in China

Biosimilar merger for Epirus and collaboration for Catalent

Epirus and Ranbaxy sign agreement for infliximab biosimilar

References
1.   GaBI Online - Generics and Biosimilars Initiative. Infliximab ‘similar biologic’ receives Indian approval [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 10]. Available from: www.gabionline.net/Biosimilars/News/Infliximab-similar-biologic-receives-Indian-approval 
2.   GaBI Online - Generics and Biosimilars Initiative. China to release biosimilars guidelines [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 10]. Available from: www.gabionline.net/Guidelines/China-to-release-biosimilars-guidelines 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.

Source: Epirus

comment icon Comments (0)
Post your comment
Related content
EMA recommends approval of two adalimumab biosimilars
ST002293
Biosimilars/News Posted 01/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010